Insurance benefits for Pfizer’s heart drug Vyndamax uncertain

Korea Biomedical Review

9 September 2021 - Pfizer’s Vyndamax (tafamidis), a treatment for transthyretin amyloid cardiomyopathy, got in the European Society of Cardiology’s list of recommended drugs for heart failure.

However, observers said it is uncertain whether the treatment would be reimbursable in Korea because of its high price.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Market access , Korea